FrancophonIA/ELRC3.0 huggingface dataset:
English: Place the Respreeza vial on an even and firm surface.
Estonian: Asetada Respreeza viaal siledale kindlale pinnale.
English: •how to prepare and givethis medicine (see the illustrated instructions at the end of this leaflet in
Estonian: • kuidas seda ravimit ette valmistada ja manustada (vt illustreeritud juhiseid selle infolehe lõpus lõigus “Teave tervishoiutöötajatele ja patsientidele, kellel sobib kasutada kodust ravi / iseendale manustamist”)
English: • 1°solvent vial of 20 ml water for injections
Estonian: • 1 lahustiviaal 20 ml süsteveega
English: Respreeza 5,000 mg powder and solvent for solution for infusion One vial contains approximately 5,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Estonian: Respreeza 5000 mg infusioonilahuse pulber ja lahusti Üks viaal sisaldab ligikaudu 5000 mg inimese alfa-1 proteinaasi inhibiitorit* vastavalt selle võimele neutraliseerida inimese neutrofiilide elastaasi.
English: ELF levels of antigenic alpha1-proteinase inhibitor and alpha1-proteinase inhibitor: NE complexes increased from baseline.
Estonian: Antigeense alfa-1 proteinaasi inhibiitori ja alfa-1 proteinaasi inhibiitori tasemed epiteeli sisepinna vedelikus: neutrofiilide elastaasi komplekside sisaldus suurenes algtasemega võrreldes.
English: Volume of distribution at steady state
Estonian: Jaotusruumala püsikontsentratsioonil
English: Respreeza 4,000 mg powder and solvent for solution for infusion One vial contains approximately 4,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Estonian: Respreeza 4000 mg infusioonilahuse pulber ja lahusti Üks viaal sisaldab ligikaudu 4000 mg inimese alfa-1 proteinaasi inhibiitorit* vastavalt selle võimele neutraliseerida inimese neutrofiilide elastaasi.
English: After reconstitution, Respreeza is given by infusion into a vein.
Estonian: Respreezat manustatakse pärast lahustamist tilkinfusiooni teel veeni.
English: After reconstitution with 76 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Estonian: Pärast lahustamist 76 ml lahustiga sisaldab lahus ligikaudu 50 mg/ml inimese alfa-1 proteinaasi inhibiitorit.
English: After reconstitution with 95 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Estonian: Pärast lahustamist 95 ml lahustiga sisaldab lahus ligikaudu 50 mg/ml inimese alfa-1 proteinaasi inhibiitorit.
English: Take the Mix2Vial set together with the blister package and vertically pierce the water for injections vial with the blue tip of the Mix2Vial set (Figure 2).
Estonian: Võtta Mix2Vial seade koos blisterpakendiga ja sisestada Mix2Vial seadme sinine teravik vertikaalselt süstevee viaali (joonis 2).
English: Respreeza 1,000 mg powder and solvent for solution for infusion One vial contains approximately 1,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Estonian: Respreeza 1000 mg infusioonilahuse pulber ja lahusti Üks viaal sisaldab ligikaudu 1000 mg inimese alfa-1 proteinaasi inhibiitorit* vastavalt selle võimele neutraliseerida inimese neutrofiilide elastaasi.
English: Human alpha1-proteinase inhibitor 5,000 mg
Estonian: Inimese alfa-1 proteinaasi inhibiitor 5000 mg
English: Wipe the rubber stopper of the Respreeza vial with antiseptic solution and allow it to dry.
Estonian: Puhastada süstevee viaali kummist punnkork antiseptilise lahusega ja lasta kuivada.
English: Invert the water for injections vial with the Mix2Vial set attached and vertically pierce the Respreeza vial with the clear tip of the Mix2Vial set (Figure 4).
Estonian: Pöörata Mix2Vial seadmega ühendatud süstevee viaal ümber ja sisestada Mix2Vial seadme värvitu teravik vertikaalselt Respreeza viaali (joonis 4).
English: Human alpha1-proteinase inhibitor 4,000 mg
Estonian: Inimese alfa-1 proteinaasi inhibiitor 4000 mg
English: Tell your doctor or healthcare professional immediately if you notice any sign of allergic reactions (for example chills, flushing, faster heartbeat, fall in blood pressure, light-headedness, rash, hives, itching, difficulty in breathing or swallowing as well as swelling of your hands,
Estonian: Öelge oma arstile või tervishoiutöötajale kohe, kui märkate Respreeza manustamise ajal allergiliste reaktsioonide tunnuseid (näiteks külmavärinad, õhetus, südametegevuse kiirenemine, vererõhu langus, uimasus, lööve, nahapõletik, kihelus, hingamis- või neelamisraskus ja käte, näo või suu turse).Teie arst või tervishoiutöötaja võib olenevalt reaktsiooni olemusest ja raskusest otsustada kas infusiooni aeglustada või selle täielikult lõpetada ja anda reaktsiooni vastu sobivat ravi.
English: Eye disorders
Estonian: Silma kahjustused silma turse
English: Take care not to touch the rubber vial stopper.
Estonian: Ärge puudutage viaali kummikorki.
English: After reconstitution with 20 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Estonian: Pärast lahustamist 20 ml lahustiga sisaldab lahus ligikaudu 50 mg/ml inimese alfa-1 proteinaasi inhibiitorit.
English: Respreeza 1,000 mg powder and solvent for solution for infusion Respreeza 1,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: Respreeza 1000 mg infusioonilahuse pulber ja lahusti Repreeza 1000 mg pulbrit (I tüüpi) klaasviaalis, suletud (bromobutüül või klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: Respreeza 4,000 mg powder and solvent for solution for infusion Respreeza 4,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: Respreeza 4000 mg infusioonilahuse pulber ja lahusti Repreeza 4000 mg pulbrit (I tüüpi) klaasviaalis, suletud (bromobutüül või klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: Respreeza 5,000 mg powder and solvent for solution for infusion Respreeza 5,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: Respreeza 5000 mg infusioonilahuse pulber ja lahusti Repreeza 5000 mg pulbrit (I tüüpi) klaasviaalis, suletud (bromobutüül või klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: Open the Mix2Vial set by peeling off the lid (Figure 1).
Estonian: ® seade, eemaldades sellelt katte (joonis 1).
English: Since alpha1-proteinase inhibitor is an endogenous human protein, it is considered unlikely that Respreeza will cause harm to the foetus when given at recommended doses.
Estonian: Alfa-1 proteinaasi inhibiitor on inimese endogeenne valk ning seetõttu ei peeta Respreeza kahjulikku toimet lootele tõenäoliseks selle manustamisel soovitatud annustes.
English: Human alpha1-proteinase inhibitor 1,000 mg
Estonian: Inimese alfa-1 proteinaasi inhibiitor 1000 mg
English: • Inspect the reconstituted solution for particulate matter and discoloration prior to administration.
Estonian: • Enne manustamist hinnata valmistatud lahust tahkete osakeste ja värvimuutuse esinemise suhtes.
English: 95 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: 95 ml süstevett (I tüüpi) klaasviaalis, suletud (klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: Home-treatment / self-administration
Estonian: Kodune ravi / ise manustamine
English: Non-clinical data reveal no special risk for humans based on safety pharmacology and short term toxicity studies.
Estonian: Farmakoloogilise ohutuse ja lühiajalise toksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: 76 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: 76 ml süstevett (I tüüpi) klaasviaalis, suletud (klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: Since human alpha1-proteinase inhibitor is an endogenous human protein, no adverse effects on fertility are expected when given at recommended doses.
Estonian: Alfa-1 proteinaasi inhibiitor on inimese endogeenne valk ning seetõttu ei peeta selle kahjulikku toimet fertiilsusele tõenäoliseks selle manustamisel soovitatud annustes.
English: 1 solvent vial of 76 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Estonian: 1 pulbriviaal ühekordseks kasutamiseks 1 lahustiviaal 76 ml süsteveega 1 ülekandeseade 20/20 (Mix2Vial seade) lahustamiseks
English: Respreeza 4,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Estonian: Respreeza 4000 mg infusioonilahuse pulber Inimese alfa-1 proteinaasi inhibiitor
English: Respreeza 5,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Estonian: Respreeza 5000 mg infusioonilahuse pulber Inimese alfa-1 proteinaasi inhibiitor
English: Respreeza 1,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Estonian: Respreeza 1000 mg infusioonilahuse pulber Inimese alfa-1 proteinaasi inhibiitor
English: Respreeza 5,000 mg powder and solvent for solution for infusion.
Estonian: Respreeza 5000 mg infusioonilahuse pulber ja lahusti.
English: Respreeza 4,000 mg powder and solvent for solution for infusion:
Estonian: Respreeza 4000 mg infusioonilahuse pulber ja lahusti:
English: A healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency will supervise the first infusions.
Estonian: Esimesed infusioonid toimuvad alfa-1 proteinaasi inhibiitori puudulikkuse ravis kogenud tervishoiutöötaja järelevalve all.
English: Respreeza 1,000 mg powder and solvent for solution for infusion:
Estonian: Respreeza 1000 mg infusioonilahuse pulber ja lahusti:
English: Respreeza 5,000 mg powder and solvent for solution for infusion:
Estonian: Respreeza 5000 mg infusioonilahuse pulber ja lahusti:
English: Respreeza contains sodium
Estonian: Respreeza sisaldab naatriumit
English: Dizziness, headache
Estonian: rindkerevalu, külmavärinad, palavik
English: 20 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Estonian: 20 ml süstevett (I tüüpi) klaasviaalis, suletud (klorobutüül) kummist punnkorgi ja alumiiniumtihendi ning eemaldatava plastkattega.
English: 1 solvent vial of 95 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Estonian: 1 pulbriviaal ühekordseks kasutamiseks 1 lahustiviaal 95 ml süsteveega 1 ülekandeseade 20/20 (Mix2Vial seade) lahustamiseks
English: Respreeza 4,000 mg powder and solvent for solution for infusion.
Estonian: Respreeza 4000 mg infusioonilahuse pulber ja lahusti.
English: Respreeza 1,000 mg powder and solvent for solution for infusion.
Estonian: Respreeza 1000 mg infusioonilahuse pulber ja lahusti.
English: MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer of the biological active substance
Estonian: Bioloogilise toimeaine tootja nimi ja aadress
English: 1 solvent vial of 20 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Estonian: 1 pulbriviaal ühekordseks kasutamiseks 1 lahustiviaal 20 ml süsteveega 1 ülekandeseade 20/20 (Mix2Vial seade) lahustamiseks
English: Paraesthesia
Estonian: Imetamine
English: Skin and subcutaneous tissue disorders
Estonian: Infusioonilahuse pulber ja lahusti
English: Paediatric population
Estonian: Nakkusetekitajad
English: Lot
Estonian: Annus
English: Dyspnoea
Estonian: Manustamine
English: One solvent vial of 95°ml water for injections One transfer set 20/20 (Mix2Vial set) for reconstitution
Estonian: Respreeza 5000 mg infusioonilahuse pulber ja lahusti: üks pulbriviaal ühekordseks kasutamiseks üks lahustiviaal 95 ml süsteveega üks ülekandeseade 20/20 (Mix2Vial seade) lahustamiseks
English: What Respreeza is
Estonian: Mis ravim on Respreeza
English: Nervous system disorders
Estonian: Infusioonilahuse pulber.
English: Administration
Estonian: Kogukliirens
English: Reporting of side effects If you get any side effects, talk to your doctor or healthcare professional.
Estonian: Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti või tervishoiutöötajaga.
English: Powder and solvent for solution for infusion.
Estonian: Infusioonilahuse pulber ja lahusti.
English: One solvent vial of 76°ml water for injections One transfer set 20/20 (Mix2Vial set) for reconstitution
Estonian: Respreeza 4000 mg infusioonilahuse pulber ja lahusti: üks pulbriviaal ühekordseks kasutamiseks üks lahustiviaal 76 ml süsteveega üks ülekandeseade 20/20 (Mix2Vial seade) lahustamiseks
English: The other side effects may include:
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
English: This summary was last updated in July 2010.
Estonian: Kokkuvõtte viimane uuendus: juuli 2010.
English: Pigs and horses should not be slaughtered for 5 days.
Estonian: Sigu ja hobuseid ei tohi tappa 5 päeva jooksul.
English: Accidental self-injection may cause pain.
Estonian: Juhuslik enesesüstimine võib tekitada valu.
English: After the last administration of Meloxidyl cattle should not be slaughtered for 15 days and the milk not used for 5 days.
Estonian: Pärast Meloxidyli viimast manustamist ei tohi veist tappa 15 päeva jooksul ja tema piima tarvitada 5 päeva jooksul.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Meloxidyl to Ceva Santé Animal on 15 January 2007.
Estonian: Euroopa Komisjon andis Meloxidyli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Ceva Santé Animal 15. jaanuaril 2007.
English: What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
Estonian: Kui pikk on aeg, millal looma ei või tappa ega tema liha tarvitada toiduks (keeluaeg)?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MELOXIDYL EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE MELOXIDYL Kokkuvõte üldsusele
English: It can be used for both acute (sudden) disorders, such as those seen after an injury, and chronic (long-term) disorders.
Estonian: Ravimit võib kasutada nii ägedate (näiteks vigastuste järel tekkivate) kui ka krooniliste (pikaajaliste) kahjustuste korral.
English: The Committee recommended that Meloxidyl should be given a marketing authorisation.
Estonian: Komitee soovitas anda Meloxidyli müügiloa.
English: In horses, anaphlylactoid (hypersensitivity) reactions can occur and should be treated symptomatically.
Estonian: Hobustel võivad tekkida anafülaktilised (ülitundlikkuse) reaktsioonid, sellisel juhul tuleb anda sümptomaatilist ravi.
English: Meloxidyl is a pale green oral suspension (1.5 mg/ml) for dogs and (0.5 mg/ml) for cats, which is mixed into the food, and a yellow solution for injection (5 mg/ml) for dogs and cats as well as solution for injection (20 mg/ml) for cattle, pigs and horses.
Estonian: Meloxidyl on kahvaturoheline suukaudne suspensioon, mida manustatakse koertele (1,5 mg/ml) ja kassidele (0,5 mg/ml) toiduga segatult, kollane süstelahus (5 mg/ml), mida manustatakse koertele ja kassidele, ning süstelahus (20 mg/ml), mida manustatakse veistele, sigadele ja hobustele.
English: Information on the prescription status of this product may be found on the label of the carton.
Estonian: Teave näidustuste kohta selle toote kasutamiseks on esitatud karbi etiketil.
English: If this happens, seek medical advice immediately and show the package leaflet or the label to the doctor.
Estonian: Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: Therefore the CVMP's view was that, as for Metacam, Meloxidyl's benefits are greater than its risks.
Estonian: Veterinaarravimite komitee oli seepärast seisukohal, et nagu Metacami korral, on Meloxidyli kasulikkus suurem kui sellega kaasnevad riskid.
English: They usually occur during the first week of treatment and tend to be temporary.
Estonian: Tavaliselt esinevad kõrvalnähud esimese ravinädala jooksul, on ajutised ja kaovad pärast ravi lõppu.
English: Meloxidyl is a ‘generic': this means that Meloxidyl is similar to a ‘reference veterinary medicinal product' already authorised in the EU (Metacam).
Estonian: Meloxidyl on geneeriline ravim: see tähendab, et Meloxidyl sarnaneb võrdlusveterinaarravimiga, millele juba on Euroopa Liidus müügiluba antud (Metacam).
English: A study looked at how Meloxidyl was absorbed and its effects in the body, in comparison with Metacam.
Estonian: Uuringus vaadeldi Meloxidyli imendumist ja toimet organismis võrreldes Metacamiga.
English: In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight temporary swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Estonian: Veised ja sead taluvad nahaalust, lihasesisest ja veenisisest manustamist hästi; vähem kui 10%-l kliinilistes uuringutes ravitud veistest täheldati pärast ravimi nahaalust manustamist kerget mööduvat turset süstekohal.
English: If someone swallows the medicinal product, the advice of a doctor should be sought immediately.
Estonian: Juhusliku neelamise korral tuleb pöörduda kohe arsti poole.
English: Other information about Meloxidyl:
Estonian: Muu teave Meloxidyli kohta
English: Why has Meloxidyl been approved?
Estonian: Miks Meloxidyl heaks kiideti?
English: Studies have been carried out to prove that Meloxidyl is ‘bioequivalent' to the reference veterinary medicinal product: this means that Meloxidyl is equivalent to Metacam in the way it is absorbed and used by the body.
Estonian: Tehtud uuringud tõendavad Meloxidyli bioekvivalentsust võrdlus-veterinaarravimiga: see tähendab, et Meloxidyl imendub ja toimib organismis samamoodi nagu Metacam.
English: In dogs and cats the side effects seen with Meloxidyl are similar to those seen with other NSAIDs and occur only occasionally.
Estonian: Koertel ja kassidel on Meloxidyli kõrvalnähud sarnalaadsed teiste mittesteroidsete põletikuvastaste ravimite kõrvalnähtudega ning neid esineb ainult aeg-ajalt.
English: What is the risk associated with Meloxidyl?
Estonian: Mis riskid Meloxidyliga kaasnevad?
English: Based on the findings of the study, Meloxidyl was considered to be bioequivalent to the reference medicinal product.
Estonian: Uuringute tulemuste põhjal on Meloxidyl bioekvivalentne võrdlusravimiga.
English: Meloxidyl is a medicinal product that contains the active substance meloxicam.
Estonian: Meloxidyl on ravim, mis sisaldab toimeainena meloksikaami.
English: What is Meloxidyl?
Estonian: Mis on Meloxidyl?
English: The benefit-risk balance may be found in module 6 of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande 6. jaotises.
English: People who are hypersensitive to NSAIDs should avoid contact with Meloxidyl.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud (allergilised), peavad kokkupuudet Meloxidyliga vältima.
English: Meloxidyl contains meloxicam, which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Estonian: Meloxidyl sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite klassi.
English: Because of this, Meloxidyl's benefit is taken as being the same as that of the reference medicinal product.
Estonian: Seetõttu peetakse Meloxidyli kasulikkust võrdseks võrdlusravimi kasulikkusega.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Meloxidyl has been shown to be bioequivalent to Metacam.
Estonian: Veterinaarravimite komitee otsustas, et Meloxidyli bioekvivalentsus Metacamiga on Euroopa Liidu nõuete kohaselt tõendatud.
English: What is Meloxidyl used for?
Estonian: Milleks Meloxidyli kasutatakse?
English: In cattle Meloxidyl injection is used to reduce clinical signs in case of acute respiratory infection with appropriate antibiotic therapy, to reduce clinical signs in case of diarrhoea in combination with oral re-hydration therapy in calves over one week of age and young, nonlactating cattle and as supportive therapy in the treatment of acute mastitis, in combination with antibiotics.
Estonian: Veistel kasutatakse Meloxidyli süstelahust ägeda respiratoorse infektsiooni kliiniliste sümptomite vähendamiseks koos sobiva antibiootikumiraviga; kõhulahtisuse kliiniliste sümptomite vähendamiseks kombineeritult suukaudse rehüdratsioonraviga üle nädala vanustel vasikatel ja noortel mittelakteerivatel veistel ning toetava ravina ägeda mastiidi raviks koos antibiootikumidega.
English: They include loss of appetite, vomiting, diarrhoea, blood in the stools and apathy (lack of vitality).
Estonian: Kõrvalnähud on näiteks isutus, oksendamine, kõhulahtisus, veriroe ning apaatia (loidus).
English: How does Meloxidyl work?
Estonian: Kuidas Meloxidyl toimib?
English: How has Meloxidyl been studied?
Estonian: Kuidas Meloxidyli uuriti?
English: In pigs Meloxidyl injection is used to reduce the symptoms of lameness and inflammation in non-infectious locomotor disorders and for supportive therapy in the treatment of puerperal septicaemia and toxaemia around farrowing (mastitis-metritis-agalactia syndrome) with appropriate antibiotics.
Estonian: Sigadel kasutatakse Meloxidyli süstelahust mittenakkuslike lokomotoorsete häirete puhul lonkamise ja põletikusümptomite vähendamiseks ning toetava ravina poegimisjärgse sepsise ja tokseemia puhul (mastiidi-metriidi-agalaktia sündroom) koos sobiva antibiootikumiraviga.
English: What benefit has Meloxidyl shown during the studies?
Estonian: Milles seisneb uuringute põhjal Meloxidyli kasulikkus?
English: Meloxidyl injection is used in cats to reduce the pain after an operation, such as spaying or minor soft tissue surgery.
Estonian: Meloxidyli süstelahust kasutatakse kassidel operatsioonijärgse valu alandamiseks pärast steriliseerimist ja väiksemaid pehmekoe operatsioone.
English: As an injection, Meloxidyl is also used to reduce the pain and inflammation after an operation, such as orthopaedic or soft tissue surgery.
Estonian: Süstelahust kasutatakse ka operatsioonijärgse valu ja põletiku alandamiseks pärast ortopeedilisi ja pehmekoe operatsioone.
English: In cats, Meloxidyl is used as an oral suspension to relieve inflammation and pain in chronic musculo-skeletal disorders as well as to relieve mild to moderate pain after an operation, such as spaying or soft tissue surgery.
Estonian: Meloxidyli suukaudset suspensiooni kasutatakse kassidel põletiku ja valu leevendamiseks krooniliste luu- ja lihaskonna kahjustuste korral ning operatsioonijärgse nõrga või mõõduka valu leevendamiseks pärast steriliseerimist ja pehmekoe operatsioone.
English: In dogs, Meloxidyl is used as an oral suspension to relieve inflammation and pain in musculoskeletal disorders.
Estonian: Meloxidyli kasutatakse koertel põletiku ja valu leevendamiseks luu- ja lihaskonna kahjustuste korral.
English: In horses Meloxidyl injection is used to relieve inflammation and pain in both acute and chronic musculo-skeletal disorders and for the relief of pain associated with colic.
Estonian: Hobustel kasutatakse Meloxidyli süstelahust põletiku ja valu leevendamiseks ägedate või krooniliste luu- ja lihaskonna kahjustuste korral ning voolmete vähendamiseks.
English: Therefore it is currently not recommended for use in these patients.
Estonian: Seetõttu praegu ei soovitata seda nendel patsientidel kasutada.
English: Current available data are described in section 5.1.
Estonian: Olemasolevat teavet on kirjeldatud lõigus 5.1.
English: Appropriate symptomatic treatment should be provided.
Estonian: Peab rakendama asjakohast sümptomaatilist ravi.
English: Frequency is not known.
Estonian: Sagedus ei ole teada.
English: Therefore, possible reduction in absorption cannot be excluded.
Estonian: Seetõttu ei saa välistada võimalikku imendumise vähenemist.